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ABBREVIATIONS AND ACRONYMS
Drugs targeting adrenoceptors (ARs) producing activation and/or inhibition are some of the most widely used therapeutic agents in clinical medicine. ARs bind and are activated by the endogenous catecholamines adrenaline and noradrenaline. α 1 -AR subtype cDNAs encoding three α 1 -AR subtypes (α 1A , α 1B , and α 1D ) have been cloned and characterized pharmacologically. [1] [2] [3] [4] [5] [6] The α 1D -ARs have been shown to have 10 to 100-fold higher affinity for the endogenous neurotransmitters norepinephrine and epinephrine compared with the α 1A -or α 1B -AR subtypes. 6 This finding provides a potentially important mechanistic rationale for targeting α 1D -ARs when treating lower urinary tract symptoms (LUTS).
Expression of α 1 -AR subtypes in animal models and afferent nerve activity modulation through α 1D -ARs in voiding function
In some animal models associated with bladder outflow obstruction (BOO), hypertension and aging have been found to complicate urinary bladder dysfunction. [7] [8] [9] [10] In each of these models an elevated expression level of α 1D -AR mRNA or α 1D -AR protein has been demonstrated ( Fig. 1 ). To counteract these pathological changes, some of which are, at least partly, caused by α 1D -AR stimulation, it is reasonable to assume that an α 1D -AR antagonist could be useful.
Expression of α 1 -AR subtype in animal models
In animal studies, Hampel et al. found that BOO produced a 6-fold increase in bladder weight vs. sham operation, and significantly increased voiding frequency. 11 Although the bladder α 1 -AR density did not increase overall, striking changes in α 1 -AR subtype expression were demonstrated.
In control animals, 70% of α 1 -AR mRNA was the α 1A subtype, 5% was α 1B , and 25% was α 1D , whereas in obstructed animal bladders, α 1 -AR expression changed to 23% α 1A , 2% α 1B , and 75% α 1D . Changes in α 1 -AR mRNA expression were of similar magnitude throughout the bladder dome, mid body, and base. Parallel changes were also evident at the protein level, with 100% α 1A -AR expression in control animals changing to 36% (mean value) in animals with a 5-fold or greater increase in bladder weight. The data of Hampel et al. are suggestive, but whether a change in α 1D density could have functional consequences was not investigated. However, it has been shown pharmacologically that elevated urinary frequency in obstructed rats was decreased with tamsulosin (α 1A/1D antagonist) but not with 5-Me-urapidil (α 1A antagonist). 12 Further, Barendrecht et al. reported that relaxation responses to the endogenous agonist noradrenaline through β-AR are turned into α 1 -AR-mediated contraction responses in BOO, possibly due to up-regulation of α 1D -AR. 10 These findings support the hypothesis that the α 1D -ARs are mechanistically involved in the development of storage symptoms, and they are plausible targets for therapeutic interventions to achieve a stable bladder condition and control storage symptoms. Recently, changes in the distribution of the α 1 -AR subtype in the urinary bladder have been demonstrated in a rat BOO model. 13 The study was conducted with a sham group and a BOO group to evaluate the impact of BOO on α 1 -AR expression.
While there was no major difference in weight between the sham and BOO groups, urinary bladder weight was higher in the BOO group (0.76 g) than in the sham group (0.11g). differed from that in control rats and was characterized by a decrease in bladder capacity and micturition volume, as well as by an increase in nonvoiding bladder contractions. 7 The results have furthermore suggested differences in smooth muscle and neuronal responsiveness to norepinephrine between SHR and control rats. The distribution of α 1 -AR subtype in the urinary bladder of SHRs has been reported; rats were assigned to 2 groups, and the reference group was fed a normal chow diet, while another group was fed experimental chow that contained 8% NaCl. 14 Blood pressure increased slightly depending on the NaCl diet. While the expression of α 1D -AR subtype was increased in the NaCl diet group, the expression of α 1A -AR subtype was dramatically decreased in both bladder urothelium and smooth muscle layers. The expression level of α 1D -AR mRNA was similarly increased, and that of α 1A was decreased. These findings suggest that the dynamics of α 1 -AR expression could partly contribute to bladder function.
Using rat bladder, Dmitrieva et al. investigated whether aging affects expression of α 1D -AR and whether α 1D -AR mediates contraction. 9 Immunofluorescent staining for α 1D -AR was detected in sections of the urothelium. Furthermore, Western blotting confirmed more α 1D -AR in the urothelium in aged rats than in young rats. Moreover, phenylephrine increased intravesical pressure in a concentration-dependent manner in both young and aged rats, and the effect of phenylephrine was significantly greater in aged than in young rats. It was also found that prazosin and BMY7378, an α 1D -AR antagonist, decreased the contractile response induced by phenylephrine in a concentration-dependent manner in aged and young rats. BMY7378 produced significantly greater inhibition in aged rats, while prazosin did not. These findings suggest that α 1D -AR was overexpressed in aged rat urothelium, resulting in enhancement of the contractile response.
Voiding function and afferent nerve activity modulation through α 1D -AR
To examine whether a molecule is really important in some physiological responses, animal genetic models may have advantages. Two groups recently reported that the α 1D -AR subtype plays a with Western blotting and immunohistochemistry, and that inhibition of these receptors affects reflex voiding through an afferent nerve decrease. 17 The rather selective α 1D -AR antagonist naftopidil prolonged the intercontraction interval during continuous infusion cystometrograms in conscious rats (143% of the control value) and suppressed the excitatory effect of intravesical infusion of 0.1% acetic acid on the intercontraction interval (220%). Naftopidil inhibited the bladder afferent nerve activity induced by bladder distension (32%) and acetic acid infusion (30%) and decreased ATP levels in the bladder perfusate during bladder distention (37%). Sugaya et al. also reported the effects of naftopidil on the urinary ATP level and bladder activity after bladder stimulation in rats using continuous cystometry with 0.1% acetic acid. 18 The shortened interval between bladder contractions with the acetic acid solution was recovered with naftopidil treatment. The urinary ATP level increase caused by the infusion of acetic acid was less with naftopidil. Therefore, naftopidil's inhibitory effect on bladder activity may be partly due to blocking ATP release from the bladder epithelium.
A relationship between sensory nerve activation and an increased voiding reflex response is well known. Cold stress was found to significantly decrease the voiding interval, micturition volume, and bladder capacity in conscious rats. 19 TRPM8 expression on the skin partly mediated the micturition responses. 20 But how does α 1D -AR affect the above relationship? A novel and interesting finding associated with cold stress stimulation was recently reported using OVX rats, 21 which have been shown to have a decreased sensory afferent nerve threshold. Cold stress stimulates the skin TRPM8.
The TRPM8-positive area in the skin was significantly higher (2-times) in OVX rats than in sham rats. In the OVX rats, the voiding interval was shortened from 3.0 min to 2.0 min, and the bladder capacity was smaller, from 0.73 mL to 0.39 mL under the low temperature condition as compared to the sham rats. Furthermore, naftopidil, an α 1D -AR antagonist, blocked the OVX-induced effects (voiding interval, 4.7 min; bladder capacity, 0.83 mL). Therefore, the increased TRPM8 in OVX rats may result in α 1D -AR mediated detrusor overactivity induced by cold stress under afferent nerve activation.
CLINICAL STUDIES

α 1 -AR subtypes in the human lower urinary tract
Historically, Malloy et al. found species heterogeneity in α 1 -AR subtype expression (human vs. rat), with α 1D predominating in human detrusor. 22 Total α 1 -AR expression in human bladder was 6 fmol/mg total protein. Although significantly less than the α 1 -AR density in human prostate, bladder α 1 -AR expression is 3 times higher than the density in the human coronary artery. 23 At a subtype level, α 1D -ARs are twice as abundant as α 1A -ARs in human detrusor at both the mRNA and protein levels; no α 1B -ARs were found in human detrusor. Overall α 1D -AR expression in human tissue is more limited than that of other α 1 -AR subtypes. 
Functional responses of α 1 -AR in obstructed bladder
Nomiya et al. found that α 1 -ARs were expressed at low levels in human bladder, and α 1D -AR mRNA was increased 1.8 times in obstructed patients compared with the control group, but the difference was not significant. 25 Their functional study showed that phenylephrine at concentrations storage of experimentally infused contrast medium. 28 Expressions of α 1A -and α 1B -AR mRNAs in bladder mucosa from two groups (group 1: FDV ≤200 mL and/or SDV ≤ 300 mL; group 2: FDV ≥ 201 mL and/or SDV ≥ 301 mL) revealed no significant differences between the groups with respect to α 1A -and α 1B -AR mRNA levels. However, mucosa from the first group of patients had significantly more α 1D -AR mRNA than did that from the latter group of patients. There seem to be many molecular causes of storage symptoms, [29] [30] [31] [32] not all necessarily involving urothelial α 1 -ARs.
Nevertheless, the finding of a relationship between urodynamic sensory parameters and the expression levels of urothelial α 1 -AR mRNAs suggests that α 1D -ARs may play an important role in storage symptoms in male LUTS patients.
What is the role of the α 1D -ARs in the human bladder?
Since the nonselective α 1 -AR antagonist terazosin relieves nocturia, as assessed by frequency volume charts (FVCs), 33 one (or more) α 1 -AR subtypes must be responsible for this effect. Both tamsulosin, which is an α 1A/1D -AR selective antagonist (rather α 1A -AR selective), and naftopidil, which is an α 1D/1A -AR selective antagonist (rather α 1D -AR selective), reduce the nocturnal frequency in FVC by decreasing nocturnal urine volume. 34, 35 By contrast, silodosin, which is an α 1A -AR highly selective antagonist, does not decrease the number of nighttime voidings in FVC. 36 Then, is there evidence for α 1D -AR-related LUTS that was obtained by comparing the effects of a rather α 1A -AR selective antagonist and a rather α 1D -AR selective antagonist on bladder storage function? Nishino et al. reported interesting evidence from a PFS by comparing the two drugs in a randomized, cross-over design. 37 This study was conducted with an average prostate size of 20 mL in patients with severe symptoms (total IPSS ≥ 20). Tamsulosin and naftopidil caused no significant difference in voiding symptoms or total IPSS, but relief of storage symptoms, especially nocturia, was significantly greater with naftopidil. In PFS, moreover, the increases in the maximum desired volume and the first desired volume were higher with naftopidil than with tamsulosin. In 7 subjects who showed disappearance of involuntary contractions, disappearances were found in 5 subjects in each cross-over period. In one subject, however, involuntary contractions disappeared during the first naftopidil period, but they returned after the switch to tamsulosin. In another subject, the cross-over to naftopidil resulted in disappearance of involuntary contractions, although the contractions continued with tamsulosin. In addition, both drugs decreased BOO grade. Kakizaki et al. have also investigated detrusor overactivity using a filling cystometry procedure in BPH patients with total IPSS storage symptom scores (frequency, urgency, and nocturia) ≥ 7. 38 In nine patients who had detrusor overactivity before naftopidil treatment, filling cystometry was repeated after treatment.
Bladder volume at first desire to void increased significantly from 174 ± 92 mL to 259 ± 109 mL.
These investigations support the suggestion that α 1D -AR may play an important role, at least in part, in sensory afferent nerve activity.
α 1A -or α 1D -AR subtype dominant in patients with BPH
Initial studies examining the α 1 -AR subtype in human prostate using RNase protection assays and in situ hybridization approaches revealed that α 1A -AR predominates at the RNA level. 39 However, recent evidence demonstrated that, in addition to α 1A -AR, the α 1D -AR subtype was also present to a significant extent in human prostate using the real time RT-PCR procedure. 40 This study demonstrated that the median expression levels (interquartile range) of α 1A -AR and α 1D -AR were 1.25 (0.66-2.45) and 1.18 (0.71-2.27) × 1,000 copies/β-actin, respectively, with no significant difference. Furthermore, the ratio of the mean expression level of each subtype to total α 1 -AR was 41.2% and 49.1% for α 1A -and α 1D -AR mRNAs, respectively. The correlation between the expression of α 1 -AR subtype mRNA in the prostate and the clinical efficacy of subtype-selective α 1 -AR antagonists was also examined. 41 Patients who did not have malignant tumors based on prostate biopsy results were divided into two groups and given either tamsulosin or naftopidil. The efficacy of tamsulosin and naftopidil differed depending on the dominant α 1 -AR subtype in the prostate. Tamsulosin was more effective in patients with dominant expression of the α 1A -AR subtype, whereas naftopidil was more effective in those with dominant expression of the α 1D -AR subtype.
Although this theory may not be clinically applicable for all BPH patients because of the inconvenience of biopsy, the α 1 -AR subtype mRNA expression level in the prostate could be a predictor of the efficacy of subtype selective α 1 -AR antagonists. Genetic differences may be responsible for the diverse responses to these drugs.
SUMMARY
There is evidence that targeting only α 1A -AR may not provide comprehensive therapy for LUTS associated with BPH/BPO. The presence of α 1D -ARs in the lower urinary tract suggests that this subtype may play an important role in the pathophysiology of male LUTS. Fig.1 The expression level of α 1D -adrenoceptor (AR) mRNA or α 1D -AR protein increases by bladder outlet obstruction, hypertension and/or aging. This may be related to the male lower urinary symptoms, and α 1D -AR may become the target of the therapy.
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